Australian biotech market watch 01/06/09
Monday, 01 June, 2009
All Ordinaries are up across the board by 1.5% as further signs of recovery were being warmly welcomed by stock markets around the world. In line with the rise, health indices are up 1.1% after high volumes of trading compared to a fairly deflated week last week. CSL Limited (ASX:CSL) up 45c to $29.65 on the back of the US Government placing a $230 million dollar order to produce Novel A (H1N1) influenza vaccine antigen. Other risers include Probiotec (ASX:PBP), up 11c to $1.86 and Sonic Healthcare (ASX:SHL), which lifted 2.5% to $12.12. Flurotechnics bucked the trend, plummeting a dramatic 64.3% to 25c and CathRx (ASX:CXD) dropped 4c to 51c after releasing its quarterly investor update.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
